Banque Cantonale Vaudoise Raises Position in DexCom, Inc. $DXCM

Banque Cantonale Vaudoise grew its holdings in DexCom, Inc. (NASDAQ:DXCM) by 338.2% in the 1st quarter, HoldingsChannel.com reports. The fund owned 30,080 shares of the medical device company’s stock after buying an additional 23,216 shares during the quarter. Banque Cantonale Vaudoise’s holdings in DexCom were worth $1,888,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of DXCM. Reflection Asset Management purchased a new position in DexCom in the fourth quarter valued at $25,000. CVA Family Office LLC increased its holdings in DexCom by 48.5% during the 4th quarter. CVA Family Office LLC now owns 450 shares of the medical device company’s stock worth $30,000 after purchasing an additional 147 shares during the period. MCF Advisors LLC acquired a new stake in DexCom in the 4th quarter valued at about $32,000. ORG Partners LLC boosted its stake in shares of DexCom by 124.3% in the 4th quarter. ORG Partners LLC now owns 507 shares of the medical device company’s stock valued at $34,000 after buying an additional 281 shares during the period. Finally, DV Equities LLC purchased a new position in shares of DexCom in the 4th quarter valued at about $36,000. Hedge funds and other institutional investors own 97.75% of the company’s stock.

DexCom Price Performance

Shares of NASDAQ:DXCM opened at $70.14 on Friday. The company’s fifty day moving average price is $67.65 and its 200 day moving average price is $68.08. DexCom, Inc. has a 12 month low of $54.11 and a 12 month high of $89.98. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.95 and a quick ratio of 1.64. The firm has a market capitalization of $27.06 billion, a P/E ratio of 29.97, a P/E/G ratio of 1.13 and a beta of 1.45.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Thursday, April 30th. The medical device company reported $0.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.47 by $0.09. DexCom had a net margin of 19.31% and a return on equity of 33.33%. The company had revenue of $1.19 billion during the quarter, compared to the consensus estimate of $1.17 billion. During the same quarter in the prior year, the firm posted $0.32 earnings per share. DexCom’s revenue for the quarter was up 15.0% on a year-over-year basis. As a group, sell-side analysts predict that DexCom, Inc. will post 2.57 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

DXCM has been the topic of a number of recent research reports. BTIG Research restated a “buy” rating and set a $85.00 target price on shares of DexCom in a research note on Monday, March 9th. Deutsche Bank Aktiengesellschaft assumed coverage on shares of DexCom in a report on Tuesday. They set a “buy” rating and a $86.00 price target for the company. Raymond James Financial restated a “strong-buy” rating and issued a $91.00 price objective on shares of DexCom in a report on Monday, June 8th. TD Cowen reiterated a “buy” rating and set a $95.00 target price (up from $75.00) on shares of DexCom in a research note on Wednesday, June 10th. Finally, Sanford C. Bernstein set a $77.00 target price on DexCom in a report on Friday, May 1st. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $84.88.

Insider Activity

In other DexCom news, Director Mark G. Foletta sold 4,000 shares of DexCom stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $74.13, for a total transaction of $296,520.00. Following the transaction, the director owned 52,852 shares of the company’s stock, valued at $3,917,918.76. The trade was a 7.04% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bridgette P. Heller sold 1,012 shares of the business’s stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $60.01, for a total value of $60,730.12. Following the completion of the sale, the director owned 25,007 shares of the company’s stock, valued at approximately $1,500,670.07. This represents a 3.89% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 46,694 shares of company stock worth $3,343,977 over the last ninety days. 0.28% of the stock is owned by corporate insiders.

DexCom Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.